GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>85-1 for this deal must be close to a record, certainly a record for a phase 3 drug.<

A reflection of the fact that the ratio of ATryn potential in acquired deficiencies to ATryn potential in HD is a large number.

From the standpoint of acquired deficiencies, ATryn is effectively a phase-2 drug rather than a phase-3 drug or a BLA drug.



Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”